Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

Show other versions (1)

<p>Romiplostim was effective, safe, and well-tolerated over 6–12 months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia (ITP). This report describes up to 5 years of weekly treatment with romiplostim in 292 adult ITP patients in a long-term, single-arm, open-...

Popoln opis

Bibliografske podrobnosti
Main Authors: D. J. Kuter, J. B. Bussel, A. Newland, R. I. Baker, R. M. Lyons, J. Wasser, J.-F. Viallard, G. Macik, M. Rummel, K. Nie, S. Jun
Format: Article
Jezik:Russian
Izdano: ABV-press 2015-01-01
Serija:Онкогематология
Teme:
thrombopoiesis
thrombopoietic agents
TPO receptor agonists
platelets
autoimmunity
Online dostop:http://oncohematology.abvpress.ru/index.php/ongm/article/view/123

Internet

http://oncohematology.abvpress.ru/index.php/ongm/article/view/123

Podobne knjige/članki